- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03859908
Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries
Iodine-Povidone Alcohol Compared to Chlorhexidine Alcohol as Preoperative Antiseptics in Major Abdominal Elective Clean Contaminated Surgery
Study Overview
Status
Conditions
Detailed Description
Preoperative antiseptic Chlorhexidine based on alcohol has been established as gold standard of care for clean contaminated wounds. It was compared to Iodine solutions non-alcohol based. There is a question about alcohol based solution was a confounder in the comparison. The aim of this study is to compare the efficacy of both solutions alcohol based, 0.7% iodine povacrylex plus 74% alcohol, against gluconate chlorhexidine 2% plus 70% alcohol, in clean contaminated wounds, in major abdominal elective surgeries, in a wider range than colorectal surgeries, Materials and methods. With a pragmatic randomized, phase 4, controlled clinical trial. Comparison of two antiseptic solutions, using manufacturer (3M) sterile appliers' for both products, Food and Drugs Agency approved.
Quality of data will be assured by first training all surgeons and residents besides researchers in the study protocol for protocol compliance in subject identification, randomization moment, and follow up. There is a plan for weekly monitoring of protocol compliance, and monthly data monitoring and auditing from Faculty of Medicine Research Unit.
Monitoring and auditing will comply protocol compliance and data integrity against subject's medical records and random interviews of patients in their post-surgical control.
Surgical Site Infection definitions are those taken from Centers for Disease Control definitions.
Standard Operating Procedures will be established in all moments of the trial, from subject identification, informed consent, recruitment, randomization process in the operating room, and data collection in pre specified files for data collection and data management. Protocol compliance and Standard Operating Procedures compliance will be monitored by Principal Investigator constantly. Report of adverse events will be done in accordance to Salvadoran National ethics committee Standard Operating Procedures as also any other communication such as protocol deviance or amendments. Previous research has not reported adverse events, but we will be expectant to their appearance.
Sample size was calculated for a total of 964 subjects, 482 in each group, using statistics software, were we established a statistic significant level for a bilateral hypothesis of 95% and a power of 80%, based on previous research of comparison of both solutions to get a probability of SSI of 4.2% in Chlorhexidine group against 8.6% in Iodine povacrylex group.
We will establish a strict follow up of patients in the 30 days considered as post-operative time, by enabling the whole public health system to integrate in subjects´, surgical care (primary care) to diminish the probability of missing data.
Data analysis will be done following "intention to treat" analysis principle. Primary outcome will be any kind of Surgical Site Infection, categorical variable, will be analyzed with chi square for a bilateral hypothesis, and also measure the difference with risk ratio and its 95% confidence interval.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
San Salvador, El Salvador, 0000
- Hospital Nacional Rosales
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Elective surgery categorized as clean contaminated surgery Major abdominal
-
Exclusion Criteria:
- American Society of Anesthesia III-IV
- Laparoscopic cholecystectomy
- Inguinal hernias classification I, II
- Obese subjects with Body Mass Index more than 35 or malnourished
- immunocompromised subjects
- neoplasia Preoperative hospital stay more than 7 days allergic to any of the solutions used in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Iodine-Povacrylex Alcohol
Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention.
Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
|
As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Other Names:
|
|
Active Comparator: Chlorhexidine Alcohol
Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention.
Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
|
As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical site infection
Time Frame: Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
infections of the incision or organ or space that occur after surgery.
|
Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Superficial surgical site infection
Time Frame: Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
Infection that occurs after surgery and involves only skin and subcutaneous tissue of the incision
|
Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
|
Deep surgical site infection
Time Frame: Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
Infection that occurs after surgery that involves deep soft tissues of the incision (for example, fascial and muscle layers)
|
Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
|
Organ/space SSI
Time Frame: Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
Infection that occurs after surgery that involves any part of the body deeper than the fascial/muscle layers that is opened or manipulated during the operative procedure
|
Date of event occurs within 30 days after any operative procedure (where day 1 = the procedure date)
|
|
Skin reaction
Time Frame: Date of event occurs within 7 days after surgery (where day 1= the procedure date
|
Any kind of irritation or skin reaction after applying the solution
|
Date of event occurs within 7 days after surgery (where day 1= the procedure date
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maria-Virginia Rodriguez, MD, FACS, Universidad de El Salvador
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Iodine alcohol Trial
- CNEIS/2018/049 (Other Identifier: Comite Nacional de Etica de Investigacion en Salud)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
If we decide to share IPD, it will be: study protocol, statistical analysis. Criteria to share: for systematic reviews we could share also individual data collected, after the study is published.
The study was stopped for recruitment due to COVID-19 emergency and elective surgeries diminished, and then the product used expired. Couldn't achieve not even 2% of Sample size
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Site Infection
-
Gundersen Lutheran Medical FoundationGundersen Lutheran Health SystemCompletedSurgical Site Infection | Superficial Surgical Site Infection | Deep Surgical Site Infection | Organ/Space Surgical Site InfectionUnited States
-
King Faisal Specialist Hospital & Research CenterEnrolling by invitationSurgical Site Infections | Surgical Site Infection After Major SurgerySaudi Arabia
-
Singapore General HospitalNovem Healthcare Pte LtdTerminatedSuperficial Surgical Site InfectionSingapore
-
Halmstad County HospitalCompleted
-
MinaPharm PharmaceuticalsRecruitingSurgical Site InfectionsEgypt
-
Karolinska University HospitalStockholm South General HospitalRecruitingPostoperative Surgical Site InfectionSweden
-
Washington University School of MedicineCompleted
-
Region SkaneVinnovaCompleted
-
Population Health Research InstituteCompletedSurgical Site InfectionsCanada
-
University of RochesterSage Products, Inc.Completed
Clinical Trials on Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML
-
Maastricht University Medical CenterBayerCompletedCoronary Artery Disease | Coronary StenosisNetherlands
-
University of Texas Southwestern Medical CenterTerminatedBreast CancerUnited States
-
Solventum US LLC3MCompletedBacterial Reduction on Skin Flora Post-product ApplicationUnited States
-
David MarcinekStealth BioTherapeutics Inc.Recruiting
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
Fundación para el Fomento de la Investigación Sanitaria...Hospital Universitario Virgen de la Arrixaca; Hospital Universitario Fundación... and other collaboratorsCompleted
-
Leiden University Medical CenterU.S. Food and Drug Administration (FDA)RecruitingChronic Opioid Use | Opioid Induced Respiratory DepressionNetherlands
-
University of Missouri-ColumbiaCompletedConstipation Drug InducedUnited States
-
Sintetica SACross Research S.A.Completed
-
Alkermes, Inc.Completed